Call Us: 888-488-5750

Facebook Linkedin

Drug Shortages and Stockpiling: What You Need to Know

In recent years, drug shortages have become a major concern for healthcare systems around the world. The COVID-19 pandemic has only amplified this issue, as the demand for certain drugs has skyrocketed while the supply chain has been disrupted. This has resulted in shortages of essential medicines and has raised questions about how to prepare for such scenarios in the future.

According to a recent report by Reuters , Europe’s drug shortages may get even worse in the coming years. This is because of a combination of factors, including increased demand due to the aging population, supply chain disruptions, and issues with the pharmaceutical manufacturing process. The article also mentions that the COVID-19 pandemic has highlighted the need for more resilient supply chains and the need to better prepare for future crises.

So, what can be done to address the issue of drug shortages? One solution is to engage in stockpiling, or the act of building up a reserve of essential drugs. By having a stockpile of drugs on hand, healthcare systems can ensure that they have a sufficient supply even in the event of a crisis. However, this is easier said than done. Stockpiling drugs requires a significant investment, as well as careful planning and coordination. It is important to carefully consider the drugs that are most essential, the quantity that is needed, and the best way to store the drugs so that they remain effective.

Another factor to consider is the financial impact of stockpiling. The cost of stockpiling drugs can be substantial, and it is important to carefully weigh the benefits against the costs. Some countries have implemented stockpiling programs, while others have relied on the private sector to step in and provide drugs in the event of a shortage.

In conclusion, the issue of drug shortages is a complex and pressing problem that requires a multi-faceted approach. Stockpiling is one solution, but it requires careful consideration and investment. It is important to work together to find a solution that ensures that essential drugs are readily available in times of crisis and that the health and well-being of patients is protected.

Pharma Tariffs and Specialty Drug Cost Management: What Health Plans and TPAs Should Be Watching

On April 2nd, the White House signed a proclamation imposing new tariffs on patented pharmaceutical products under Section 232 of the Trade Expansion Act of 1962, the same national security trade authority underlying longstanding tariffs on steel and aluminum. The headline rate is 100%. But for health plans and TPAs managing specialty drug costs, that number requires context before it becomes useful for strategic rebate management and financial planning.

Read More »
April 17, 2026

When Drug Negotiation Reaches Part B

For years, Medicare drug price negotiation was mostly discussed as a Part D story. That changed in January, when CMS selected 15 drugs for the third cycle of negotiation, including the first drugs payable under Medicare Part B. Negotiations take place in 2026, and any negotiated prices from this cycle take effect in 2028.

Read More »
March 27, 2026